AzTrials
AzTrials

Chronic Obstructive Pulmonary DiseasePhase 3NCT00250679

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

A Phase 3 study testing Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID and Formoterol 12 ųg BID in people with Chronic Obstructive Pulmonary Disease and Bronchitis, run by Sumitomo Pharma America, Inc. at 60 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD). Read more about this study

Who is it for?
Ages 35 years and older
What is being tested?
Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID and Formoterol 12 ųg BID
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
443 participants
Where
60 sitesUnited States
Study dates
Oct 2005to Oct 2007
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male and female subjects must be at least 35 years old at the time of consent
  • Subjects must have a pre-established, documented primary clinical diagnosis of non-asthmatic COPD or are referred for diagnosis of non-asthmatic COPD
  • Subjects must have a >=15 pack-year smoking history and a baseline breathlessness severity grade of >=2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at Visits 1 and 2
  • Female subjects <=65 years of age must have a negative serum pregnancy test, females of childbearing potential must be using an acceptable method of birth control
  • Subjects must be in general good health.

Who cannot join

  • Subjects with a history of asthma, with the exception of asthma diagnosed in childhood
  • Subjects with a blood eosinophil count >5% of total white blood cell count
  • Subjects have had a febrile illness within 72 hours (3 days) before Screening Visit 1
  • Subjects with a chest x-ray that suggests a diagnosis other than COPD (e.g., diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions)

Trial locations and contacts

60 sites in 1 country.

60 sites in 1 country

United States60 sites
  • Study site

    Albuquerque, New Mexico

  • Study site

    Ann Arbor, Michigan

  • Study site

    Atlanta, Georgia, 30309

  • Study site

    Baltimore, Maryland

  • Study site

    Bay Pines, Florida, 33744

  • Study site

    Birmingham, Alabama

  • Study site

    Brandon, Florida

  • Study site

    Carmichael, California

  • Study site

    Chapel Hill, North Carolina

  • Study site

    Charleston, South Carolina

  • Study site

    Charlotte, North Carolina

  • Study site

    Chester, Maryland

  • Study site

    Cincinnati, Ohio

  • Study site

    Columbia, South Carolina

  • Study site

    Danville, Virginia

  • Study site

    Denver, Colorado

  • Study site

    East Providence, Rhode Island

  • Study site

    East Slidell, Louisiana

  • Study site

    Evansville, Indiana

  • Study site

    Fullerton, California

  • Study site

    Gainesville, Florida, 32605

  • Study site

    Hartford, Connecticut

  • Study site

    Houston, Texas

  • Study site

    Jasper, Alabama

  • Study site

    Katy, Texas

  • Study site

    Knoxville, Tennessee

  • Study site

    Lafayette, Louisiana

  • Study site

    Lake Oswego, Oregon

  • Study site

    Little Rock, Arkansas

  • Study site

    Long Beach, California

  • Study site

    Marietta, Georgia

  • Study site

    Medford, Oregon, 97504

  • Study site

    Metairie, Louisiana

  • Study site

    Mobile, Alabama

  • Study site

    Morgantown, West Virginia

  • Study site

    Normal, Illinois

  • Study site

    Panama City, Florida

  • Study site

    Paramount, California

  • Study site

    Pittsburgh, Pennsylvania

  • Study site

    Rancho Mirage, California

  • Study site

    Richmond, Virginia

  • Study site

    Saint Charles, Missouri

  • Study site

    San Antonio, Texas

  • Study site

    San Diego, California

  • Study site

    Simpsonville, South Carolina

  • Study site

    Spartanburg, South Carolina

  • Study site

    Spokane, Washington

  • Study site

    St Louis, Missouri, 63117

  • Study site

    St Louis, Missouri

  • Study site

    Statesville, North Carolina, 28625

  • Study site

    Sunset, Louisiana

  • Study site

    Swarthmore, Pennsylvania

  • Study site

    Tacoma, Washington

  • Study site

    Tampa, Florida

  • Study site

    Topeka, Kansas

  • Study site

    Union, South Carolina, 29379

  • Study site

    Walnut Creek, California

  • Study site

    Wheaton, Maryland

  • Study site

    Wilmington, North Carolina

  • Study site

    Winston-Salem, North Carolina

Other trials in United States

About this study

Official title: Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 μg and 25 μg Arformoterol Tartrate Inhalation Solution BID in Subjects With Chronic Obstructive Pulmonary Disease

To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).

Read the detailed description

This is a double-blind, double-dummy, multicenter, randomized, active-controlled, parallel group, outpatient, safety study to evaluate the long term safety of arformoterol in the treatment of subjects with COPD. Study participation will be over approximately 6 months. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Being tested
Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID, Placebo
Keywords
COPD, chronic bronchitis, emphysema
Medical subject headings
Pulmonary Disease, Chronic Obstructive, Bronchitis, Emphysema, Bronchitis, Chronic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Arformoterol tartrate inhalation solutionDrug

    Also called Brovana®

    Arformoterol 15 ųg BID by nebulization

  • Arformoterol 25 ųg BIDDrug

    Also called Brovana, R,R formoterol

    Arformoterol 25 ųg BID by nebulization

  • Formoterol 12 ųg BIDDrug

    Also called Foradil, R,S-formoterol

    Formoterol fumarate 12 ųg BID via aerolizer/DPI

  • PlaceboDrug

    Placebo nebule or placebo aerolizer

Study groups in NCT00250679
Study groupRoleWhat they receive
Formoterol 12 ųg 2x/dayActive comparatorNot described
Receives: Drug: Formoterol 12 ųg BID; Drug: Placebo
Arformoterol 15 ųg 2x/dayExperimentalNot described
Receives: Drug: Arformoterol tartrate inhalation solution; Drug: Placebo
Arformoterol 25 ųg 2x/dayExperimentalNot described
Receives: Drug: Arformoterol 25 ųg BID; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations

    Percent of participants with the adverse event specified.

    SOC = system organ class.

    Measured: Six months

Secondary outcomes (30)
  1. Number of Participants With New 24-Hour Holter Monitoring Alerts

    New holter monitoring alerts are defined as those alerts that occurred post-randomization and were not present at baseline.

    Measured: Visit 6 (week 27)

  2. Number of Participants With Potentially Clinically Significant Glucose Evaluations

    Patients with glucose values that met low (<=40 mg/dL) or high (>=175 mg/dL) criteria were considered potentially clinically significant.

    Measured: visit 6 (week 27)

  3. Number of Participants With Potentially Clinically Significant Potassium Evaluations

    Patients with potassium values that met low (<=3 mEq/L) or high (>=6 mEq/L) criteria were considered potentially clinically significant.

    Measured: visit 6 (week 27)

  4. Number of Participants With New 12-Lead Electrocardiogram (ECG) Alerts

    New Electrocardiogram (ECG) alerts are defined as those alerts that occurred post-treatment and were not present at baseline.

    Measured: visit 6 (week 27)

  5. Inspiratory Capacity Changes From Baseline

    Mean Change in Inspiratory Capacity values from baseline (baseline assessment obtained at Visit 2, pre-dose). Spirometry measurements collected within 6 hours following in-clinic rescue/supplemental medications use were excluded from analysis.

    Measured: weeks 0,3,13,26

  6. 6-Hour Peak Changes From Baseline in Forced Expiratory Volume (FEV1)

    The 6 hour peak change from baseline is the maximum of the post-dose change values through 6 hours at each visit.

    Measured: weeks 0,3,13,26

  7. Number of Participants With Potentially Clinically Significant Heart Rate

    Number of subjects with a heart rate that was lower/higher than a set limit and increased/decreased from set baseline limit in beats per minute (bpm)

    Measured: visit 6 (week 27)

  8. Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Days Used Per Week

    Supplemental medication usage is recorded throughout the study. MDI stands for metered dose inhaler.

    Measured: Screening (day-14 to 0) and Treatment (week 0 - 26)

  9. Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day

    Supplemental medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.

    Measured: Screening (day-14 to 0) and Treatment (week 0 - 26)

  10. Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Days Used Per Week

    Rescue medication usage during the study. MDI stands for metered dose inhaler.

    Measured: Screening (day-14 to 0) and Treatment (week 0 - 26)

  11. Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day

    Rescue medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.

    Measured: Screening (day-14 to 0) and Treatment (week 0 - 26)

  12. Time-Normalized Area Under the Curve (nAUC) From 0 to 6 Hrs for Forced Expiratory Volume in One Second (FEV1) Changes From Baseline

    Area under the change from baseline curve from 0 to 6 hours. Time-normalized AUC (0-6 hrs) was derived using the linear trapezoidal method.

    Measured: weeks 0,3,13,26

  13. Transitional (Relative Change in) Dyspnea Index

    The transitional focal score (-9 to 9) is the sum of relative change from baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores (each -3 to 3 scale). A Transitional Dyspnea Index score of -9 represents a maximum degradation of all three tests; a score of 9 represents a maximum improvement of all three tests.

    Measured: weeks 13, 26

  14. Number of Participants With an Improved Transitional Dyspnea Index

    The number of participants with a transitional focal score (range -9 to 9) of >=1 improvement. Transitional focal score compares current health against baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.

    Measured: weeks 13, 26

  15. Forced Expiratory Volume in One Second (FEV1) Changes From Baseline for 24 Hour Post Dose Timepoint (Trough)

    The 24 hour trough is the FEV1 value obtained 24 hours post first dose. This value is compared to the baseline FEV1 value.

    Measured: weeks 0,3,13,26

  16. Subject Global Evaluations Change From Baseline

    The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1=much better and 7=much worse. Ratings were assessed relative to the subject's initial entry into the study.

    Measured: weeks 13, 26

  17. Investigator Global Evaluations Change From Baseline

    The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse. Ratings were assessed relative to the subject's initial entry into the study.

    Measured: weeks 13, 26

  18. BODE Index

    The BODE index (0=relative health and 10=severe chronic obstructive pulmonary disease) is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the 6-minute walk test. Scores were derived using pre-dose assessments from each visit.

    Measured: Baseline (visit 2), weeks 13, 26

  19. 6-Minute Walk: Change From Baseline in the Distance Walked in 6 Minutes

    Mean change from baseline in distance walked (meters)

    Measured: Post-Dose weeks 0, 13, 26

  20. Mean Change From Baseline in St. George's Respiratory Questionnaire

    Scores are expressed as a mean change from baseline of overall impairment (total score). The questionnaire has a scale of 100 which represents worst possible health status to 0 which indicates best possible health status.

    Measured: weeks 13, 26

  21. Number of Participants With a >=4 Unit Improvement on the St. George's Respiratory Questionnaire

    Scores are expressed as the number of participants with >= 4 unit improvement in overall impairment (total score), where 100 represents worst possible health status and 0 indicates best possible health status.

    Measured: Visit 4 (week 13) , Visit 5 (week 26)

  22. Modified Medical Research Council Dyspnea Questionaire

    Scores range from 0 to 4, with a score of 4 indicating that a subject is too breathless to leave the house or becomes breathless when dressing or undressing. The highest numbered question to which the subject answered 'Yes' is the Dyspnea Scale Score.

    Measured: Baseline (visit 2), weeks 13, 26

  23. Percent (%) of Participants With an Improved Transitional Dyspnea Index

    The percentage of participants with a transitional focal score (range -9 to 9) of >=1 improvement. Transitional focal score is the sum of the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.

    Measured: visits 4 (week 13), visit 5 (week 26)

  24. Percent (%) of Participants With a >=4 Unit Improvement in the St. George's Respiratory Questionaire

    Percent of participants with a >=4 unit improvement in the overall impairment (total score) of the St. George's Respiratory Questionaire. This questionaire uses a 100 - 0 scale, where 100 represents the worst possible health status and 0 indicates the best possible health status.

    Measured: visit 4 (week 13), visit 5 (week 26)

  25. Mean Values for the 6-Minute Walk Test: Distance Walked in Meters

    This test measures the participants' level of fitness. It is a measure of the distance the participant can walk in 6 minutes.

    Measured: Baseline (Visit 2), week 13, week 26

  26. Mean Values for Investigator Global Evaluations

    The investigator global evaluation is reported by the study investigator. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.

    Measured: Baseline (Visit 2), Weeks 13, 26

  27. Mean Values for St. George's Respiratory Questionnaire

    A questionnaire to assess respiratory health. Scores are expressed as a percentage of overall impairment (total score), where 100 represents the worst possible health status and 0 indicates best possible health status.

    Measured: Baseline (Visit 2), weeks 13, 26

  28. Mean Values for Subject Global Evaluations

    The subject global evaluation is reported by study subjects/participants. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.

    Measured: Baseline (Visit 2), weeks 13, 26

  29. Mean Values for Inspiratory Capacity

    Inspiratory capacity is the maximum volume that can be inhaled.

    Measured: Baseline (Visit 2), Weeks 3, 13, 26

  30. Mean Values for Forced Expiratory Volume in One Second (FEV1)

    Forced Expiratory Volume in one second

    Measured: Baseline (Visit 2), weeks 3, 13, 26

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Nov 2005 (estimated)
  2. Study startOct 2005
  3. Primary completionOct 2007
  4. Study completionOct 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
443 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00250679
Sponsor's protocol ID
091-061
Status last verified
May 2012
First submitted
4 Nov 2005
Last updated
4 Jun 2012
Data monitoring committee
Yes

Publications

  • Hanania NA, Donohue JF, Nelson H, Sciarappa K, Goodwin E, Baumgartner RA, Hanrahan JP. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb;7(1):17-31. doi: 10.3109/15412550903499498.

    PubMed 20214460

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID and Formoterol 12 ųg BID in people with Chronic Obstructive Pulmonary Disease and Bronchitis, run by Sumitomo Pharma America, Inc. at 60 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Jun 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 60 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Feb 2009). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations (time frame: Six months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00250679, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in